Contact Us
-
VIVIN DRUGS & PHARMACEUTICALS PRIVATE LIMITED No. 8-2-293/82/A/234 & 235, TF-1, 3rd floor, Empire square, Road No: 36, Jubilee hills, Hyderabad-500033, Telangana State, INDIA
Preloader Close
Product List API’s – ready for Commercial offerings after successful validation in R&D
| API Name |
Regulatory Status |
CAS Number |
Therapeutic Category |
|---|---|---|---|
| DARUNAVIR |
Documentation in Process for US-DMF |
206361-99-1 |
Anti-viral |
| ETORICOXIB |
Documentation in Process for US-DMF |
202409-33-4 |
Anti-Inflammatory |
| RIVAROXABAN |
Documentation in Process for US-DMF |
366789-02-8 |
Anticoagulant |
| SITAGLIPTIN PHOSPHATE MONOHYDRATE |
Documentation in Process for US-DMF |
654671-77-9 |
Anti-diabetic |
| SITAGLIPTIN BASE |
Documentation in Process for US-DMF |
486460-32-6 |
Anti-diabetic |
Proposed Products – Anti Cancer Under validation in R&D
| S.No. |
API Name |
CAS No |
Therapeutic Category |
|---|---|---|---|
| 1 |
Bortezomib |
179324-69-7 |
antineoplastic agents |
| 2 |
Carmustine |
154-93-8 |
alkylating agents |
| 3 |
Dasatinib |
302962-49-8 |
kinase inhibitors |
| 4 |
Docetaxel Trihydrate |
148408-66-6 |
antineoplastic agent |
| 5 |
Erlotinib HCl |
183319-69-9 |
kinase inhibitors |
| 6 |
Gefitinib |
184475-35-2 |
kinase inhibitors |
| 7 |
Gemcitabine HCl |
122111-03-9 |
Antineoplastics, Antimetabolite |
| 8 |
Imatinib Mesylate |
152459-95-5 |
kinase inhibitors |
| 9 |
Nilutamide |
63612-50-0 |
antiandrogens |
| 10 |
Paclitaxel |
33069-62-4 |
antimicrotubule agents |
| 11 |
Capecitabine |
154361-50-9 |
antimetabolites |
| 12 |
Tofacitinib citrate |
540737-29-9 |
Janus kinase (JAK) inhibitors |
| 13 |
Palbociclib |
571190-30-2 |
kinase inhibitors |
Proposed Products - Other Therapeutic Category Under validation in R&D
| S.No. |
Product Name |
CAS No |
Therapeutic Category |
|---|---|---|---|
| 1 |
Celecoxib (USP/EP) |
169590-42-5 |
nonsteroidal anti-inflammatory drugs (NSAIDs) |
| 2 |
Atorvastatin Calcium(USP/EP) |
344423-98-9 |
HMG-CoA reductase inhibitors (statins) |
| 3 |
Oseltamivir Phosphate |
204255-11-8 |
neuraminidase inhibitors |
| 4 |
Dabigatran Etexilate Mesylate |
872728-81-9 |
Anticoagulants, |
| 5 |
Lingaliptin |
668270-12-0 |
dipeptidyl peptidase-4 (DPP-4) inhibitors |
| 6 |
Vildagliptin |
274901-16-5 |
oral anti-hyperglycemic agent (anti-diabetic drug) |
| 7 |
Gemifloxacin |
175463-14-6 |
fluoroquinolones |
| 8 |
ospemifene |
128607-22-7 |
selective estrogen receptor modulators (SERM) |
| 9 |
Mirabegron |
223673-61-8 |
beta-3 adrenergic agonists |
| 10 |
Macitentan |
441798-33-0 |
endothelin receptor antagonists |
| 11 |
Pirfenidone |
53179-13-8 |
idiopathic pulmonary fibrosis |
| 12 |
Alogliptin Benzoate |
850649-62-6 |
type 2 diabetes |
| 13 |
Ticagrelor |
274693-27-5 |
antiplatelet medications |
| 14 |
Celecoxib (USP/EP) |
169590-42-5 |
nonsteroidal anti-inflammatory drugs (NSAIDs) |
| 15 |
Atorvastatin Calcium(USP/EP) |
344423-98-9 |
HMG-CoA reductase inhibitors (statins) |
| 16 |
Oseltamivir Phosphate |
204255-11-8 |
neuraminidase inhibitors |
| 17 |
Dabigatran Etexilate Mesylate |
872728-81-9 |
Anticoagulants, |
| 18 |
Lingaliptin |
668270-12-0 |
dipeptidyl peptidase-4 (DPP-4) inhibitors |
| 19 |
Vildagliptin |
274901-16-5 |
oral anti-hyperglycemic agent (anti-diabetic drug) |
| 20 |
Gemifloxacin |
175463-14-6 |
fluoroquinolones |
| 21 |
ospemifene |
128607-22-7 |
selective estrogen receptor modulators (SERM) |
| 22 |
Mirabegron |
223673-61-8 |
beta-3 adrenergic agonists |
| 23 |
Macitentan |
441798-33-0 |
endothelin receptor antagonists |
| 11 |
Pirfenidone |
53179-13-8 |
idiopathic pulmonary fibrosis |
| 24 |
Alogliptin Benzoate |
850649-62-6 |
type 2 diabetes |
| 25 |
Ticagrelor |
274693-27-5 |
antiplatelet medications |